The association of mid-regional pro-adrenomedullin and mid-regional pro-atrial natriuretic peptide with mortality in an incident dialysis cohort

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Gouya, Ghazaleh ^a   Sturm, Gisela ^b   Lamina, Claudia ^b   Zitt, Emanuel ^c   Freistätter, Otto ^d   Struck, Joachim ^e   Wolzt, Michael ^a   Knoll, Florian ^c   Lins, Friederike ^d   Lhotta, Karl ^c,d   Neyer, Ulrich ^c,d   Kronenberg, Florian ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c ACADEMIC TEACHING HOSPITAL FELDKIRCH   (Austria)

^d Vorarlberg Institute for Vascular Investigation and Treatment VIVIT   (Austria)

^e THERMO FISHER SCIENTIFIC   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MIDREGIONAL PROADRENOMEDULLIN; MIDREGIONAL PROATRIAL NATRIURETIC PEPTIDE; PEPTIDE; UNCLASSIFIED DRUG; ADRENOMEDULLIN; ATRIAL NATRIURETIC FACTOR; MIDREGIONAL PRO ATRIAL NATRIURETIC PEPTIDE, HUMAN; MIDREGIONAL PRO-ATRIAL NATRIURETIC PEPTIDE, HUMAN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; FEMALE; HEMODIALYSIS; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERITONEAL DIALYSIS; PROGNOSIS; PROTEIN BLOOD LEVEL; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; BLOOD; KAPLAN MEIER METHOD; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TREATMENT OUTCOME;

ADRENOMEDULLIN; AGED; ATRIAL NATRIURETIC FACTOR; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 79952344314     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017803     Document Type: Article

References (30)

1. de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, et al. (2009) Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 302: 1782-1789.
2. Kronenberg F, Neyer U, Lhotta K, Trenkwalder E, Auinger M, et al. (1999) The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol 10: 1027-1036.
3. Kwan BCH, Kronenberg F, Beddhu S, Cheung AK, (2007) Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol 18: 1246-1261.
4. Nishikimi T, (2007) Adrenomedullin in the kidney-renal physiological and pathophysiological roles. Curr Med Chem 14: 1689-1699.
5. Franz M, Woloszczuk W, Horl WH, (2001) Plasma concentration and urinary excretion of N-terminal proatrial natriuretic peptides in patients with kidney diseases. Kidney Int 59: 1928-1934.
6. Dieplinger B, Mueller T, Kollerits B, Struck J, Ritz E, et al. (2009) Pro-A-type natriuretic peptide and pro-adrenomedullin predict progression of chronic kidney disease: the MMKD Study. Kidney Int 75: 408-414.
7. Kronenberg F, (2009) Emerging risk factors and markers of chronic kidney disease progression. Nat Rev Nephrol 5: 677-689.
8. Nakatani T, Naganuma T, Masuda C, Sugimura T, Uchida J, et al. (2003) The prognostic role of atrial natriuretic peptides in hemodialysis patients. Blood Purif 21: 395-400.
9. Odar-Cederlof I, Ericsson F, Theodorsson E, Kjellstrand CM, (2003) Neuropeptide-Y and atrial natriuretic peptide as prognostic markers in patients on hemodialysis. ASAIO J 49: 74-80.
10. Rutten JH, Korevaar JC, Boeschoten EW, Dekker FW, Krediet RT, et al. (2006) B-type natriuretic peptide and amino-terminal atrial natriuretic peptide predict survival in peritoneal dialysis. Perit Dial Int 26: 598-602.
11. Zoccali C, Mallamaci F, Benedetto FA, Tripepi G, Parlongo S, et al. (2001) Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 12: 1508-1515.
12. Goto T, Takase H, Toriyama T, Sugiura T, Kurita Y, et al. (2002) Increased circulating levels of natriuretic peptides predict future cardiac event in patients with chronic hemodialysis. Nephron 92: 610-615.
13. Yoshihara F, Horio T, Nakamura S, Yoshii M, Ogata C, et al. (2005) Adrenomedullin reflects cardiac dysfunction, excessive blood volume, and inflammation in hemodialysis patients. Kidney Int 68: 1355-1363.
14. Moertl D, Berger R, Struck J, Gleiss A, Hammer A, et al. (2009) Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. J Am Coll Cardiol 53: 1783-1790.
15. Khan SQ, O'Brien RJ, Struck J, Quinn P, Morgenthaler N, et al. (2007) Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol 49: 1525-1532.
16. Maier C, Clodi M, Neuhold S, Resl M, Elhenicky M, et al. (2009) Endothelial markers may link kidney function to cardiovascular events in type 2 diabetes. Diabetes Care 32: 1890-1895.
17. Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, et al. (2009) Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 302: 49-57.
18. Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, et al. (2010) Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 55: 2062-2076.
19. Sturm G, Lamina C, Zitt E, Lhotta K, Lins F, et al. (2010) Sex-specific association of time-varying hemoglobin values with mortality in incident dialysis patients. Nephrol Dial Transplant 25: 2715-2722.
20. Morgenthaler NG, Struck J, Alonso C, Bergmann A, (2005) Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 51: 1823-1829.
21. Morgenthaler NG, Struck J, Thomas B, Bergmann A, (2004) Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 50: 234-236.
22. Schwaiger JP, Lamina C, Neyer U, König P, Kathrein H, et al. (2006) Carotid plaques and their predictive value for cardiovascular disease and all-cause mortality in hemodialysis patients considering renal transplantation- A decade follow-up. Am J Kidney Dis 47: 888-897.
23. Schwaiger JP, Neyer U, Sprenger-Mähr H, Kollerits B, Mündle M, et al. (2006) A simple score predicts future cardiovascular events in an inception cohort of dialysis patients. Kidney Int 70: 543-548.
24. Yoshihara F, Ernst A, Morgenthaler NG, Horio T, Nakamura S, et al. (2007) Midregional proadrenomedullin reflects cardiac dysfunction in haemodialysis patients with cardiovascular disease. Nephrol Dial Transplant 22: 2263-2268.
25. Meeran K, O'Shea D, Upton PD, Small CJ, Ghatei MA, et al. (1997) Circulating adrenomedullin does not regulate systemic blood pressure but increases plasma prolactin after intravenous infusion in humans: a pharmacokinetic study. J Clin Endocrinol Metab 82: 95-100.
26. Hinson JP, Kapas S, Smith DM, (2000) Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev 21: 138-167.
27. Pio R, Martinez A, Unsworth EJ, Kowalak JA, Bengoechea JA, et al. (2001) Complement factor H is a serum-binding protein for adrenomedullin, and the resulting complex modulates the bioactivities of both partners. J Biol Chem 276: 12292-12300.
28. Ala-Kopsala M, Magga J, Peuhkurinen K, Leipala J, Ruskoaho H, et al. (2004) Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments. Clin Chem 50: 1576-1588.
29. Lo CS, Chen CH, Hsieh TJ, Lin KD, Hsiao PJ, et al. (2009) Local action of endogenous renal tubular atrial natriuretic peptide. J Cell Physiol 219: 776-786.
30. Lewis LK, Smith MW, Yandle TG, Richards AM, Nicholls MG, (1998) Adrenomedullin(1-52) measured in human plasma by radioimmunoassay: plasma concentration, adsorption, and storage. Clin Chem 44: 571-577.